SAN DIEGO, Nov. 6, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (“Mirati”) (NASDAQ: MRTX) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its drug development programs.
“Over the last quarter we made substantial progress against our goals, including strengthening our balance sheet,” said Charles M. Baum, M.D., Ph.D., president and CEO, Mirati. “In September, we completed a successful financing that enables us to advance all of our clinical development programs to the next stage.”
Recent and Upcoming Pipeline Highlights
Operations:
- Completed a public offering of 2.25 million shares of common stock at $45.00 per share in September 2015, generating net proceeds of $94.9 million
MGCD265: Molecularly targeted kinase inhibitor
- World Conference on Lung Cancer 2015: Presented data demonstrating the favorable tolerability and clinical efficacy of MGCD265, with confirmed responses in non-small cell lung cancer (NSCLC) patients with MET and Axl gene amplification
- The poster can be found on the Company’s website at www.mirati.com
- Additional information about this clinical trial of MGCD265 is available at www.clinicaltrials.gov using identifier: NCT00697632
- The Company expects to initiate a single arm, open-label Phase 2 study in NSCLC patients, with driver alterations in MET, by the end of the year. MET alterations occur in up to 7% of NSCLC patients
MGCD516: Molecularly targeted kinase inhibitor
- European Cancer Congress (ECC) 2015: Presented interim clinical data from the ongoing Phase 1 dose escalation study of MGCD516 in patients with advanced solid tumors
- Demonstrated that MGCD516 is well tolerated with a favorable pharmacokinetic profile
- The poster can be found on the Company’s website at www.mirati.com
- Additional information about this clinical trial of MGCD516 is available at www.clinicaltrials.gov using identifier: NCT02219711
- The Company has initiated the expansion cohorts in selected patients and expects preliminary data in 2016. The initial focus will be on NSCLC in patients with genetic driver mutations, including RET, Trk and DDR
Mocetinostat: Class I & IV HDAC inhibitor
- Announced an immuno-oncology clinical trial collaboration with MedImmune, the global biologic research and development arm of AstraZeneca, to evaluate the safety and efficacy of mocetinostat in combination with durvalumab, an investigational anti-PD-L1 immune checkpoint inhibitor. The initial Phase 2 study will be conducted in patients with NSCLC and is expected to begin in the first half of 2016
Third Quarter 2015 Financial Results
Cash, cash equivalents, and short-term investments were $138.0 million at September 30, 2015, compared to $29.3 million at December 31, 2014. In September 2015, the Company completed a public offering of 2.25 million shares of its common stock, generating net proceeds of $94.9 million. In February 2015, the Company completed a public offering of 2.6 million shares of its common stock, generating net proceeds of $48.4 million.
Research and development expenses for the third quarter of 2015 were $14.6 million, compared to $6.9 million for the same period in 2014. Research and development expenses for the nine months ended September 30, 2015 were $34.0 million, compared to $19.0 million for the same period in 2014. The increases in research and development expenses primarily reflect costs to advance the clinical development of its three oncology development programs, MGCD265, MGCD516 and mocetinostat. General and administrative expenses for the third quarter of 2015 were $4.2 million, compared to $3.7 million for the same period in 2014. General and administrative expenses for the nine months ended September 30, 2015 were $12.2 million, compared to $9.3 million for the same period in 2014. The increases in general and administrative expenses primarily reflect higher compensation costs including non-cash stock-based compensation expense.
Other income and expense, net, for the third quarter of 2015 was expense of less than $0.1 million compared to income of $1.9 million for the same period in 2014. Other income and expense, net, for the nine months ended September 30, 2015 was income of $0.1 million compared to expense of $4.6 million for the same period in 2014. Other income and expense, net, for the third quarter and nine months ended September 30, 2014 primarily reflects losses arising from the change in fair value of our warrant liability. During 2014, we amended the warrant agreements to allow for the warrants to be denominated in U.S. dollars.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
